Phase I Study of Decitabine (Dacogen) and Bortezomib (Velcade) in Acute Myeloid Leukemia.

Trial Profile

Phase I Study of Decitabine (Dacogen) and Bortezomib (Velcade) in Acute Myeloid Leukemia.

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2014

At a glance

  • Drugs Bortezomib (Primary) ; Decitabine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Jul 2012 Planned end date changed from 1 Jan 2009 to 1 Jan 2100 as reported by ClinicalTrials.gov.
    • 04 Apr 2012 Results presented at the 103rd Annual Meeting of the American Association for Cancer Research.
    • 10 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top